Vertex’s Kaftrio + Ivacaftor Receive the EC’s Approval to Treat Cystic Fibrosis in People Aged 12 Years and Older

 Vertex’s Kaftrio + Ivacaftor Receive the EC’s Approval to Treat Cystic Fibrosis in People Aged 12 Years and Older

Vertex’s Kaftrio + Ivacaftor Receive the EC’s Approval to Treat Cystic Fibrosis in People Aged 12 Years and Older

Shots:

  • The EC has granted MAA to Kaftrio (ivacaftor/tezacaftor/lumacaftor) + ivacaftor (150mg) to treat people with CF aged ≥12yrs. with one F508del mutation and one minimal function mutation (F/MF), or two F508del mutations (F/F) in the CFTR gene
  • The MAA is based on two P-III studies i.e. a 24wks. study in 403 people with one F508del mutation and one F/MF & a 4wks. study in 107 people with two F508del mutations (F/F). The studies demonstrated improvements in lung function (1EPs) and all 2EPs and were generally well-tolerated in both studies
  • Kaftrio is designed to increase the quantity and function of the F508del-CFTR protein at the cell surface

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Bloomberg

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post